(Reuters) – The U.S. Food and Drug Administration on Friday gave accelerated approval for the expanded use of Daiichi Sankyo and AstraZeneca’s drug to treat patients with a type of …
Topic:
AstraZeneca
-
-
By Divya Chowdhury and Savio Shetty DAVOS, Switzerland (Reuters) – Drugmaker AstraZeneca has not seen any supply issues so far due to Red Sea shipping disruptions, a top executive told …
-
(Reuters) – Shares in AstraZeneca fell more than 4% on Wednesday after the publication of an abstract on its experimental precision drug’s use in lung cancer in a late-stage trial …
-
By Maggie Fick (Reuters) -AstraZeneca said on Friday its experimental precision drug had slowed the progression of a common type of breast cancer in a late-stage trial, a boost for …
-
By Daniel Wiessner (Reuters) – AstraZeneca Pharmaceuticals LP has been sued in the U.S. by a former senior director who claims the drugmaker refused to pay her nearly $130,000 in …
-
(Reuters) – AstraZeneca said on Thursday that a combination of its cancer drug Lynparza and abiraterone has been approved in the United States for the treatment of BRCA-mutated metastatic castration-resistant …
-
FRANKFURT – Long-serving AstraZeneca boss Pascal Soriot said on Friday he expects to work with the new chairman-designate of the London-listed drugmaker, who will take over in 2023, for many …
-
SEOUL – South Korea on Thursday authorised AstraZeneca PLC’s antibody-based therapy for preventing COVID-19 infection in people with a poor immune response, increasing its options as it works to ease …
-
By Natalie Grover LONDON – AstraZeneca and Daiichi Sankyo’s Enhertu extended survival by more than six months in patients with a form of advanced breast cancer compared to standard chemotherapy, …
-
BEIJING -Chinese authorities summoned officials of AstraZeneca China regarding an investigation of suspected medical insurance fraud by the company’s employees, the National Healthcare Security Administration (NHSA) said on Saturday. The …